Evidence map›Paper›PMID 39324520›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2024

Self-reported hearing loss is associated with faster cognitive and functional decline but not diagnostic conversion in the ADNI cohort.

Alyssa A Miller, Emily S Sharp, Selena Wang, Yize Zhao, Adam P Mecca, Christopher H van Dyck, Ryan S O'Dell, Alzheimer's Disease Neuroimaging Initiative (ADNI)

4 registry-linked trialsAbstract read
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00106899 completednot on this map

Alzheimer's Disease Neuroimaging Initiative

TypeobservationalSponsorAlzheimer's Disease Cooperative Study (ADCS)Ran2005 to 2011Enrolled818ConditionsAlzheimer's DiseaseArmsMagnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Lumbar Puncture (LP)
NCT01078636 completednot on this map

Alzheimer's Disease Neuroimaging Initiative Grand Opportunity

TypeobservationalSponsorAlzheimer's Disease Cooperative Study (ADCS)Ran2010 to 2012Enrolled342ConditionsMild Cognitive Impairment, Alzheimer's Disease
NCT01231971 completednot on this map

Alzheimer's Disease Neuroimaging Initiative 2

TypeobservationalSponsorUniversity of Southern CaliforniaRan2011 to 2017Enrolled1,182ConditionsMild Cognitive Impairment (MCI), Alzheimer's Disease (AD), Significant Memory Concern (SMC), Early Mild Cognitive Impairment (EMCI)ArmsFlorbetapir, Flortaucipir
NCT02854033 completednot on this map

Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3)

TypeobservationalSponsorUniversity of Southern CaliforniaRan2016 to 2024Enrolled1,141ConditionsMild Cognitive Impairment (MCI), Alzheimer's Disease (AD)
3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. [Mediation analysis of plasma phosphorylated tau217 in the association between periodontitis and mild cognitive impairment].Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology · 2025
    Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Alyssa A MillerAlzheimer's Disease Research Unit, Yale University School of Medicine, New Haven, Connecticut, USA.
Emily S SharpAlzheimer's Disease Research Unit, Yale University School of Medicine, New Haven, Connecticut, USA.
Selena WangDepartment of Biostatistics, Yale University School of Public Health, New Haven, Connecticut, USA.
Yize ZhaoDepartment of Biostatistics, Yale University School of Public Health, New Haven, Connecticut, USA.
Adam P MeccaAlzheimer's Disease Research Unit, Yale University School of Medicine, New Haven, Connecticut, USA.
Christopher H van DyckAlzheimer's Disease Research Unit, Yale University School of Medicine, New Haven, Connecticut, USA.
Ryan S O'DellAlzheimer's Disease Research Unit, Yale University School of Medicine, New Haven, Connecticut, USA.ORCID 0000-0001-7673-6661
Alzheimer's Disease Neuroimaging Initiative (ADNI)

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Yale Study Support Suite (YES3): Dashboard and Web Portal Software Supporting Research Workflow through integrated, customizable REDCap External ModulesP30AG021342 · NIA · YALE UNIVERSITY · PI Albert C Shaw · 2002 to 2026
$37.9M
Yale Alzheimer Disease Research CenterP30AG066508 · NIA · YALE UNIVERSITY · PI STEPHEN M STRITTMATTER, CHRISTOPHER H VAN DYCK · 2020 to 2026
$30.2M
Integrative analysis for patient-centered outcomes and time-to-event data in Alzheimer's diseaseRF1AG081413 · NIA · YALE UNIVERSITY · PI SUN, YIFEI, ZHAO, YIZE · 2023 to 2023
$2.3M
Novel integrative imaging genetics analysis for Alzheimer's disease riskand progressionRF1AG068191 · NIA · YALE UNIVERSITY · PI ZHAO, YIZE · 2021 to 2021
$1.9M
Novel integrative imaging genetics analysis for Alzheimer's disease riskand progressionR01AG068191 · NIA · YALE UNIVERSITY · PI ZHAO, YIZE · 2024 to 2025
$1.2M
AbbVie, Alzheimer's AssociationAlzheimer's Drug Discovery FoundationAraclon BiotechBioClinica, Inc.Biogen; Bristol-Myers Squibb CompanyCereSpir, Inc.Cogstate; Eisai Inc.Department of Defense W81XWH-12-2-0012Elan Pharmaceuticals, Inc.Eli Lilly and CompanyEuroImmunF. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.FujirebioGE HealthcareIXICO Ltd.Janssen Alzheimer Immunotherapy Research &Development, LLC.Johnson & Johnson Pharmaceutical Research & Development LLC.LumosityLundbeckMerck & Co., Inc.Meso Scale Diagnostics, LLC.NCATS NIH HHS UL1 TR001863NeuroRx ResearchNeurotrack TechnologiesNIA NIH HHS P30 AG021342NIA NIH HHS P30AG021342NIA NIH HHS P30 AG066508NIA NIH HHS P30AG066508NIA NIH HHS R01 AG068191NIA NIH HHS RF1 AG068191NIA NIH HHS RF1AG068191NIA NIH HHS RF1 AG081413NIA NIH HHS RF1AG081413NIA NIH HHS U01 AG024904NIH HHS U01 AG024904Northern California Institute for Research and EducationNovartis Pharmaceuticals CorporationPfizer Inc.Piramal ImagingServierTakeda Pharmaceutical Companythe Alzheimer's Disease Neuroimaging Initiative (ADNI)The Canadian Institutes of Health Researchthe National Institute of Biomedical Imaging and BioengineeringTransition Therapeutics
6 · The paper itself

Abstract

introductionHearing loss is identified as one of the largest modifiable risk factors for cognitive impairment and dementia. Studies evaluating this relationship have yielded mixed results.

methodsWe investigated the longitudinal relationship between self-reported hearing loss and cognitive/functional performance in 695 cognitively normal (CN) and 941 participants with mild cognitive impairment (MCI) enrolled in the Alzheimer's Disease Neuroimaging Initiative.

resultsWithin CN participants with hearing loss, there was a significantly greater rate of cognitive decline per modified preclinical Alzheimer's cognitive composite. Within both CN and MCI participants with hearing loss, there was a significantly greater rate of functional decline per the functional activities questionnaire (FAQ). In CN and MCI participants, hearing loss did not significantly contribute to the risk of progression to a more impaired diagnosis. DISCUSSION: These results confirm previous studies demonstrating a significant longitudinal association between self-reported hearing loss and cognition/function but do not demonstrate an increased risk of conversion to a more impaired diagnosis. CLINICAL TRIAL REGISTRATION INFORMATION: NCT00106899 (ADNI: Alzheimer's Disease Neuroimaging Initiative, clinicaltrials.gov), NCT01078636 (ADNI-GO: Alzheimer's Disease Neuroimaging Initiative Grand Opportunity, clinicaltrials.gov), NCT01231971 (ADNI2: Alzheimer's Disease Neuroimaging Initiative 2, clinicaltrials.gov), NCT02854033 (ADNI3: Alzheimer's Disease Neuroimaging Initiative 3, clinicaltrials.gov). HIGHLIGHTS: Hearing loss is a potential modifiable risk factor for dementia. We assessed the effect of self-reported hearing loss on cognition and function in the ADNI cohort. Hearing loss contributes to significantly faster cognitive and functional decline. Hearing loss was not associated with conversion to a more impaired diagnosis.

Indexed as

Alzheimer DiseaseCognitive DysfunctionDisease ProgressionHearing LossSelf ReportAgedAged, 80 and overCognitionCohort StudiesFemaleHumansLongitudinal StudiesMaleNeuropsychological TestsRisk Factorscognitionconversionhearing lossmemoryneuropsychological testing

Identifiers

PMID39324520
PMCPMC11567835

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.